Tuberculosis still remains in the top 10 cause of death, worldwide.
- TB is a bacterial infection which requires antibiotic treatment
- Cultures to identify the bacterium can take a long time- days
- Pushing us to treat with broad spectrum antibiotics
- Increasing risk of further antibiotic resistance
1.What is it?
- Small portable device
- results within a few hours
- able to identify Rifampin susceptible and resistant strains of M. tuberculosis
2. Why is it important?
As numbers have been rising again with almost 25% related to patients with HIV, WHO is encouraging us to increase awareness to a “TB free world.”
This device not only allows for faster diagnosis but the more selective treatment it leads to also tackles the antibiotic resistance pandemic.
That’s 2 birds with the same stone, reserving time, energy and financial costs.
3. How does it work?
This is a bench test which can detect multiple disease markers with a single sample.
Using Gel Element Microarrays with samples has important chemistry for more accurate results as the polymer is less volatile due to increased cross-link formation.
In short, compared to monomers used previously, this improves the kinetics and signal intensities in results – click here for more information.
- DNA extracted from sample
- Array hybridisation
- Imaging data and analysis
USP: This polymer medium the sample is tested upon is a cheaper alternative to glass slides used previously drastically lowering costs of testing as well as resources.
This technology is already being used to test for hundreds of other disease markers with a single sample including:
- Genotyping for warfarin sensitivity
Liquid biopsy testing in oncology is the next step as Akonnibiosystems partner up with Righton; a Chinese diagnostics company.
5. Who’s involved?
AkonniBiosystems– a Molecular Diagnostics company with a vision to create accessible, low cost, products to enable rapid drug development, early diagnosis and increase treatment options.